Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

The purpose of this study is to determine what effects (good and bad) bevacizumab and temozolomide have on patients with neuroendocrine tumors.


Study summary:

Patients will receive temozolomide orally once daily for one week, followed by a one-week rest period. This one-week on/one week off schedule will continue for the duration of treatment unless significant side effects develop. Bevacizumab will be administered intravenously every other week. After eight weeks (two cycles), a CT scan will be performed to see how treatment affected tumor growth. Bactrim, an antibiotic, and acyclovir, an antiviral medicine, will be given in order to help prevent infection. Blood tests will be done every other week to evaluate any side effects. Once the study has been completed, a physical exam, vital signs, blood tests, and CT scan will be performed. Patients will remain on the study as long as they continue to receive benefit from the treatment and there are no serious side effects.


Criteria:

Inclusion Criteria: - Histologically documented locally unresectable or metastatic neuroendocrine tumor excluding small cell carcinoma - Measurable disease > 1cm by spiral computed tomography (CT) or > 2cm by other radiographic technique - ECOG performance status of 0-2 - Life expectancy of > 12 weeks - Prior treatment with chemotherapy is allowed - Total bilirubin < 2.0mg/dl - AST < 5x upper limit of normal (ULN) - Serum creatinine < 2.0mg/dl - Absolute neutrophil count > 1,000/mm3 - Platelets > 100,000/mm3 - International Normalized Ratio (INR) < 1.5 Exclusion Criteria: - Prior treatment with temozolomide, decarbazine or bevacizumab - Clinically apparent central nervous system metastases or carcinomatous meningitis - Clinically significant cardiovascular disease - Major surgery, open biopsy, or significant traumatic injury within 28 days - Pregnant or breast-feeding women - Chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medication - Serious, nonhealing wound, ulcer or bone fracture - Evidence of bleeding diathesis or coagulopathy - History of other disease or metabolic dysfunction


NCT ID:

NCT00137774


Primary Contact:

Principal Investigator
Matthew H. Kulke, MD
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.